Investigator

Prasenjit Dey

Roswell Park Cancer Institute, Immunology

PDPrasenjit Dey
Papers(1)
NC410, a bivalent LAI…
Collaborators(7)
Qian LiuSolomon LangermannAnna StokolosaDallas FliesJanine JosephKristopher AttwoodKunle Odunsi
Institutions(5)
Roswell Park Comprehe…Chinese Academy Of Me…Unknown InstitutionUniversity At Buffalo…University of Chicago

Papers

NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression

Abstract We previously observed that circulating human neutrophils exposed to epithelial ovarian cancer (OC) ascites fluid supernatants (ASC) and malignant effusions from other tumors acquire T cell suppressor function. Collagen motifs ligate LAIR-1, an inhibitory SHP-1-dependent checkpoint broadly expressed on immune cells. We hypothesized that NC410, a bivalent LAIR-2 construct that inhibits LAIR-1-collagen binding, would rescue neutrophil-driven T cell non-responsiveness. NC410 remodeled ASC collagen resulting in neutrophil clustering and reduction in neutrophil-T cell contact, abrogated ASC-induced neutrophil trogocytosis of T cell membranes and rescued stimulated T cell proliferation. Mean ASC pro-collagen-1α levels were >100-fold greater than serum samples. In a single-center retrospective analysis, after adjusting for age, stage and optimal debulking, ASC pro-collagen-1α and serum sLAIR-1 levels were each associated with worse overall survival (OS), and ASC LAIR-2 levels were associated with better OS. Multispectral imaging of high-grade serous ovarian cancer and non-small cell lung cancer showed highly variable LAIR-1 staining in both tumor cell and immune infiltrates. The proportion of collagen-1-positive cells was highest among tumor cells and tumor-infiltrating immune cells versus stromal immune cells, raising the potential role of tumor-associated collagen limiting immune cell infiltration into tumor. Our results support further evaluation of circulating and tumor-associated collagen products and LAIR-1 and LAIR-2 as prognostic biomarkers in advanced OC and as biomarkers for clinical response to NC410 and to other collagen- and LAIR-directed therapies.

13Works
1Papers
7Collaborators
Tumor MicroenvironmentNeoplasmsOvarian NeoplasmsCarcinoma, Ovarian EpithelialPancreatic NeoplasmsCell Line, TumorPancreatitis

Positions

2019–

Researcher

Roswell Park Cancer Institute · Immunology

Education

2019

Postdoctoral Fellow

University of Texas MD Anderson Cancer Center Children's Cancer Hospital · Cancer Biology

2013

PhD

University of Houston · Biochemistry

Country

US